

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 25, 26, and 28.

1. (withdrawn) A therapeutic agent for inhibiting vascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
2. (withdrawn) A therapeutic agent for a solid cancer comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
3. (withdrawn) A therapeutic agent for a disease pathologically caused by neovascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
4. (withdrawn) A therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
5. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits the binding between SDF-1 and CXCR4.
6. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits signaling from CXCR4 to nuclei.
7. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits the expression of CXCR4.
8. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits the expression of SDF-1.
9. (withdrawn) The therapeutic agent according to claim 5, wherein the substance inhibits SDF-1.

10. (withdrawn) The therapeutic agent according to claim 5, wherein the substance inhibits CXCR4.

11. (withdrawn) The therapeutic agent according to claim 9, wherein the substance inhibits CXCR4 in antagonistic competition with SDF-1.

12. (withdrawn) The therapeutic agent according to claim 9, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to SDF-1.

13. (withdrawn) The therapeutic agent according to claim 11, wherein the substance is one selected from the group consisting of a SDF-1-like protein, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of SDF-1, and a low molecular weight compound having a structure similar to a binding site of SDF-1.

14. (withdrawn) The therapeutic agent according to claim 12, wherein the substance is one selected from the group consisting of an anti-SDF-1 antibody, a fragment of said antibody possessing the activity of the anti-SDF-1 antibody, a fused protein possessing binding activity to SDF-1, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the CXCR4-binding site of SDF-1.

15. (withdrawn) The therapeutic agent according to claim 10, wherein the substance inhibits CXCR4 in antagonistic competition with CXCR4 for binding to SDF-1.

16. (withdrawn) The therapeutic agent according to claim 10, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to CXCR4.

17. (withdrawn) The therapeutic agent according to claim 15, wherein the substance is one selected from the group consisting of a soluble CXCR4 that antagonizes CXCR4 in the inhibition, a protein having a CXCR4-like structure, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of CXCR4, and a low molecular weight compound having a structure similar to a binding site of SDF-1.

18. (withdrawn) The therapeutic agent according to claim 16, wherein the substance is one selected from the group consisting of an anti-CXCR4 antibody, a fragment of said antibody possessing the activity of anti-CXCR4 antibody, a fused protein possessing a binding activity to CXCR4, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the SDF-1-binding site of CXCR4.

19. (withdrawn) The therapeutic agent according to claim 6, wherein the substance is an inhibitor of a signaling system located downstream of a G protein-coupled protein and is one selected from the group consisting of a MAPK cascade inhibitor, a phospholipase C (PLC) inhibitor, and a PI3 kinase inhibitor.

20. (withdrawn) The therapeutic agent according to claim 7, wherein the substance is a substance that causes apparent disappearance of CXCR4 from cells by acting on a cell membrane to vary fluidity thereof and to cause disappearance of CXCR4 from the cell membrane.

21. (withdrawn) The therapeutic agent according to claim 7, wherein the substance is a substance that inhibits the expression of CXCR4 and is one selected from the group consisting of an antigen, an antisense polynucleotide, and an antisense RNA expressed by an antisense vector, a ribosome, and an inhibitor against the expression control site of CXCR4.

22. (withdrawn) The therapeutic agent according to claim 8, wherein the substance is an antisense polynucleotide capable of inhibiting the expression of SDF-1.

23. (withdrawn) The therapeutic agent according to claim 8, wherein the substance inhibits the expression control site of SDF-1.

24. (cancelled)

25. (currently amended) A method for treating a solid cancer comprising administering a substance that inhibits ~~[[to]]~~ human CXCR4 to a ~~mammal~~ subject in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:

i) an anti-human CXCR4 antibody, or a fragment thereof possessing binding activity to CXCR4;

and

ii) an anti-human SDF-1 antibody, or a fragment thereof possessing binding activity to SDF-1.

26. (currently amended) A method for treating a disease pathologically caused by neovascularization comprising administering a substance that inhibits human CXCR4 to a subject mammal in need thereof, wherein the substance inhibits binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:

i) an anti-human CXCR4 antibody, or a fragment thereof possessing binding activity to CXCR4;

and

ii) an anti-human SDF-1 antibody, or a fragment thereof possessing binding activity to SDF-1.

27. (withdrawn) A method for repairing a tissue comprising administering a substance that inhibits the action due to CXCR4 to a mammal in need thereof.

28. (currently amended) A method for suppressing vascularization comprising administering a substance that inhibits human CXCR4 to a mammal subject in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:

i) an anti-human CXCR4 antibody, or a fragment thereof possessing binding activity to CXCR4;

and

ii) an anti-human SDF-1 antibody, or a fragment thereof possessing binding activity to SDF-1.

29. (withdrawn) A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits signaling from CXCR4 to nuclei.

30. (withdrawn) A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits the expression of SDF-1.